Skip to content

Serum Fetuin-A and COMP Levels in Knee Osteoarthritis

The Relationship Between Clinical and Radiographic Severity of Knee Osteoarthritis and Serum Fetuin-A and COMP Levels: A Controlled Cross-Sectional Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07706569
Enrollment
180
Registered
2026-07-15
Start date
2026-04-01
Completion date
2026-12-30
Last updated
2026-07-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis, Osteoarthritis, Knee

Keywords

Osteoarthritis, Knee, Fetuin-A, Cartilage Oligomeric Matrix Protein, Biological Biomarkers, Systemic Inflammation Response Index, Cross-Sectional Studies

Brief summary

The purpose of this study is to investigate the relationship between the clinical and radiographic severity of knee osteoarthritis (OA) and the serum levels of specific biomarkers, namely Fetuin-A and Cartilage Oligomeric Matrix Protein (COMP). Osteoarthritis is a degenerative joint disease characterized by cartilage breakdown and low-grade inflammation. Investigating these biomarkers may help healthcare providers better understand the disease pathology, potentially leading to earlier diagnosis and improved tracking of disease progression. The study will compare two distinct groups: a patient group consisting of 120 individuals diagnosed with Grade 2-4 knee osteoarthritis, and a control group of 60 age- and sex-matched healthy volunteers with no history of joint disorders. Participants will undergo radiographic evaluations using the Kellgren-Lawrence classification system, alongside clinical and functional assessments, including pain severity scales, mobility metrics, and functional questionnaires. Fasting blood samples will be collected from all participants to measure serum Fetuin-A and COMP levels via laboratory analysis, and the Systemic Inflammation Response Index (SIRI) will be calculated. The collected data will be statistically analyzed to determine if biomarker levels significantly correlate with the severity of knee joint degeneration and functional impairment.

Interventions

None listed

Sponsors

Antalya Training and Research Hospital
Lead SponsorOTHER_GOV
Saglik Bilimleri Universitesi
CollaboratorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

\- Diagnosis of knee osteoarthritis according to ACR (American College of Rheumatology) criteria. Knee osteoarthritis classified as Grade 2, 3, or 4 according to Kellgren-Lawrence (K-L) grading. Volunteering to participate and providing signed informed consent.

Exclusion criteria

* Secondary post-traumatic knee osteoarthritis, history of major knee injury or joint infection. Signs of acute joint inflammation (swelling, heat increase, erythema). History of knee surgery (open or arthroscopic). Systemic inflammatory or autoimmune diseases. History of malignancy. Advanced renal or hepatic disease. Diagnosis of Diabetes Mellitus. Current use of systemic corticosteroids. Symptomatic osteoarthritis in other major joints (hip, hand, ankle, spine). Active systemic infection (fever ≥ 38, cough, diarrhea, dysuria, leukocytosis, or elevated CRP).

Design outcomes

Primary

MeasureTime frameDescription
Serum Fetuin-A LevelsBaseline (At the time of enrollment / single time point measurement)Measurement of serum Fetuin-A concentration using a human-specific ELISA kit to evaluate its relationship with radiographic and clinical severity.

Secondary

MeasureTime frameDescription
Serum COMP (Cartilage Oligomeric Matrix Protein) LevelsBaseline
Radiographic Severity via Kellgren-Lawrence (K-L) ClassificationBaseline
Clinical Severity and Functional Status via WOMAC IndexBaseline
Systemic Inflammation Response Index (SIRI)Baseline(Neutrophil x Monocyte) / Lymphocyte
Pain Severity via Visual Analog Scale (VAS)Baseline
Functional Mobility via 10-Meter Walk Test (10MWT)Baseline
Lower Extremity Muscle Strength via 5-Times Sit-to-Stand Test (5x STS)Baseline

Countries

Turkey (Türkiye)

Contacts

CONTACTBurak Karaman, MD
burak2498@gmail.com+905079130762
CONTACTMeral Bilgilisoy Filiz, Assoc. Prof.
mbilgilisoy@gmail.com

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 16, 2026